Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 458,694
  • Shares Outstanding, K 17,615
  • Annual Sales, $ 116,880 K
  • Annual Income, $ -25,090 K
  • EBIT $ 10 M
  • EBITDA $ 10 M
  • 60-Month Beta 0.96
  • Price/Sales 3.77
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 92.13% ( +10.55%)
  • Historical Volatility 121.96%
  • IV Percentile 47%
  • IV Rank 28.19%
  • IV High 307.91% on 01/09/24
  • IV Low 7.41% on 10/11/24
  • Put/Call Vol Ratio 0.31
  • Today's Volume 17
  • Volume Avg (30-Day) 52
  • Put/Call OI Ratio 1.76
  • Today's Open Interest 7,302
  • Open Int (30-Day) 7,329

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.31
  • Number of Estimates 4
  • High Estimate 0.59
  • Low Estimate 0.13
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.57 +91.89%
on 10/31/24
29.82 -12.68%
on 11/12/24
+11.18 (+75.24%)
since 10/22/24
3-Month
12.00 +117.00%
on 08/23/24
29.82 -12.68%
on 11/12/24
+13.95 (+115.38%)
since 08/22/24
52-Week
7.48 +247.93%
on 07/05/24
29.82 -12.68%
on 11/12/24
+16.54 (+174.08%)
since 11/22/23

Most Recent Stories

More News
3 Ways to Invest in Small-Cap Stocks Now

With small-cap stocks surging in response to Donald Trump's re-election and the Federal Reserve's rate cut, investors can tap into this momentum through three distinct ETFs: VBK, DWAS, and UWM, each offering...

TRGP : 207.31 (-0.18%)
LMB : 102.64 (+3.68%)
MOD : 143.22 (+1.94%)
DRS : 36.25 (+1.54%)
DWAS : 102.69 (+1.99%)
AXON : 636.95 (+0.90%)
UWM : 49.33 (+3.55%)
LII : 657.69 (+1.09%)
DECK : 192.15 (+5.63%)
RIGL : 26.04 (+3.99%)
STRL : 196.51 (-0.46%)
VBK : 297.85 (+1.79%)
Rigel: Q3 Earnings Snapshot

Rigel: Q3 Earnings Snapshot

RIGL : 26.04 (+3.99%)
Rigel: Q2 Earnings Snapshot

Rigel: Q2 Earnings Snapshot

RIGL : 26.04 (+3.99%)
Rigel: Q1 Earnings Snapshot

Rigel: Q1 Earnings Snapshot

RIGL : 26.04 (+3.99%)
Rigel: Q3 Earnings Snapshot

Rigel: Q3 Earnings Snapshot

RIGL : 26.04 (+3.99%)
Rigel Announces Presentation at the Upcoming IDWeek 2023

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming oral presentation highlighting data from the FOCUS Phase 3 clinical...

RIGL : 26.04 (+3.99%)
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved...

RIGL : 26.04 (+3.99%)
Rigel to Present at the 2023 Cantor Global Healthcare Conference

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present a company...

RIGL : 26.04 (+3.99%)
Rigel to Participate in Upcoming September Investor Conferences

/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean...

RIGL : 26.04 (+3.99%)
Rigel: Q2 Earnings Snapshot

Rigel: Q2 Earnings Snapshot

RIGL : 26.04 (+3.99%)

Business Summary

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year....

See More

Key Turning Points

3rd Resistance Point 27.21
2nd Resistance Point 26.69
1st Resistance Point 26.37
Last Price 26.04
1st Support Level 25.53
2nd Support Level 25.01
3rd Support Level 24.69

See More

52-Week High 29.82
Last Price 26.04
Fibonacci 61.8% 21.29
Fibonacci 50% 18.65
Fibonacci 38.2% 16.02
52-Week Low 7.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar